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Background: Major depression disorder (MDD) is a common condition in patients suffering from acute coronary
syndrome (ACS), and depression is a risk factor for mortality following an ACS. Growing evidence suggests that
there is an intricate interplay between atherosclerosis, inflammation and depression. The aim of this study was to
investigate the role of atherosclerosis-induced inflammation in the mediation of MDD.
Methods: 87 patients without depression were recruited at the time of an ACS, evaluated at 3 and 7 days and followed
at 1, 3 and 9 months for the occurrence of a MDD as assessed by structured interviews (MINI). At each time point, they
were monitored for inflammatory markers (high sensitivity C Reactive Protein {hsCRP} and fibrinogen), cardiovascular risk
factors and atherosclerosis burden. Association between possible predictive characteristics and depression was assessed
using a multivariable logistic regression model.
Results: The overall incidence of MDD, in this population, was 28.7% [95% CI: 19.5 – 39.4] during the 9-month follow up
period. Elevated hsCRP was not associated with depression onset after an ACS (adjusted OR: 1.07 [0.77 - 1.48]; p = 0.70),
and similarly no association was found with fibrinogen. Furthermore, we found no association between hsCRP,
fibrinogen or atherosclerosis burden at any time-point, and the occurrence of a MDD (or HDRS-17 and MADRS).
The only factor associated with depression occurrence after an ACS was a previous personal history of depression
(adjusted OR: 11.02 [2.74 to 44.34]; p = 0.0007).
Conclusions: The present study shows that after an ACS, patients treated with optimal medications could have a
MDD independent of elevated hsCRP or fibrinogen levels. Personal history of depression may be a good marker
to select patients who should be screened for depression after an ACS.
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Major depression disorder (MDD) is a common condition
in patients suffering from acute coronary syndrome
(ACS), affecting approximately 20% of patients during
hospitalization and a similar proportion within the first
year after ACS [1,2]. Depressive symptoms, even in the ab-
sence of formal diagnosis of MDD, are strong independent* Correspondence: thierry.couffinhal@u-bordeaux.fr
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unless otherwise stated.predictors of cardiovascular morbidity and mortality after
ACS [3,4].
Understanding the mechanisms underlying the onset
of depression, and identifying early markers that predict
its occurrence in patients after ACS, could have major
clinical implications in both the optimal management of
depression and secondary prevention of coronary artery
disease (CAD) [5].
However, the mechanisms specifically involved in the
association between cardiovascular disease and depression
have not been clearly established. Growing evidence
suggests that there is an intricate interplay between
atherosclerosis, inflammation and depression [6]. TheseThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ferent ways: depression is frequently diagnosed in patients
with CAD and MDD is a powerful risk factor for CAD
events [7-9]. Atherosclerosis is fundamentally an inflam-
matory disease and inflammatory markers are powerful
predictors of CAD events [10,11]. MDD is associated with
an increased level of markers of inflammation and can
be induced by pro-inflammatory treatment or cytokine
therapy in medically ill patients [12-18].
Therefore, it would be reasonable to hypothesize that
the link between CAD and depression might be mediated
by inflammation. However, the causal and temporal
mechanisms underlying the inter-relationships between
CAD, inflammation and depression have not been well
characterized.
The primary objective of the present study was to in-
vestigate the prognostic value of hsCRP or fibrinogen (as
surrogate markers of inflammation) in detecting new MDD,
after an ACS. For this purpose, we excluded patients
who had a diagnosis of depression at study entry, or were
receiving treatment for depression. We hypothesized that
high, followed by low-grade systemic inflammation, after
an ACS (as measured by serum hsCRP and fibrinogen
levels), could induce and be a biological marker able to
predict depression. The secondary objective was to in-
vestigate other factors that might predict the develop-
ment of depression after an ACS.
Methods
Patients
Between May 2006 and September 2007, a total of 146
potentially eligible patients were admitted to our depart-
ment 2–3 days after an acute coronary syndrome (ACS).
The present study enrolled patients 30–75 year old with
an ACS, defined as previously reported [19]. Specific exclu-
sion criteria with respect to depression, anti-inflammatory
drugs and inflammatory diseases, were as follows:
▪A previous history of either major depressive disorder
(MDD) within the last 6 months or treatment for
depression within the last 6 months; a current diagnosis
of MDD and/or ongoing treatment for depression at the
time of hospitalization for ACS. Patients who had a
major psychiatric disorder other than affective disorders
were also excluded (e.g., schizophrenia, dementia,
present psychotic episode).
▪A treatment by steroid, COX-2 selective inhibitor
or other non-steroidal anti-inflammatory drug
(aspirin > 325 mg) for more than 7 days before
hospitalization for ACS.
▪A surgery in the last month, presence of a severe
systemic or infectious disease, autoimmune disorder,
inflammatory disorder, or HIV, treatment with dialysis,
or a malignancy with decreased life expectancy.Other exclusion criteria included unstable medical or
neurologic condition and patients who were unable to
communicate reliably (e.g., because of cognitive dysfunc-
tion or not speaking French).
The Ethics Committee review board of the hospital
(CPP SOOM III, Bordeaux) approved the study protocol,
and all participants provided informed consent prior to par-
ticipation. All standard of care cardiovascular treatments
were permitted during the trial. Concomitant medication,
including steroids, COX-2 selective inhibitors and other
non-steroidal anti-inflammatory treatments were recorded
during the study.
Acute phase management
ACS was defined and treated according to established
guidelines [20]. A coronary angiogram was performed on
each patient included in the study, allowing precise evalu-
ation of coronary lesions, and optimized acute phase
management. The most suitable treatment was delivered
during the first week, in compliance with current guide-
lines [20].
Psychiatric assessment
▪The Mini-international neuropsychiatric interview
(MINI) was used to assess the incidence of MDD.
MINI is a short structured clinical interview, which
enables researchers to make a diagnosis of psychiatric
disorders according to DSM-IV or ICD-10 [21]. Patients
were classified as having MDD or not based upon results
of the MINI.
▪The Hamilton Depression Rating Scale (HDRS-17), is
a clinician-administered questionnaire assessing the
severity of depressive symptoms, including low mood,
insomnia, agitation, anxiety and weight loss [22].
HDRS-17 assesses severity of, and change in, depressive
symptoms over time.
▪The Montgomery-Åsberg Depression Rating Scale
(MADRS), is a ten-item clinician-administered
questionnaire assessing the severity and evolution of
depressive symptoms [22]. The MADRS is one of the
most frequently used and validated observer-rated
depression scales.
Procedure
Patients meeting the inclusion criteria were invited to
participate as soon as they were medically stable and had
been informed of their diagnosis, on average 2 days after
their ACS (range, 2–4 days). After explaining the study
and obtaining written informed consent, a research psych-
ologist (S.T.) conducted all baseline psychiatric inter-
views, and gathered routine demographic data, including
age, gender, education, living arrangements, current part-
ner status, socioeconomic status and employment status
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milial and personal depression, or other psychiatric illness
was collected during hospitalization.
During the assessment period, if the MINI was positive
for a diagnosis of MDD, the patient was excluded from
the study. If it was negative, the other psychiatric inter-
views were performed, as well as an evaluation of hsCRP
and fibrinogen levels along with other classical risk factors.
All patients benefited from the CEPTA program with
an optimization of secondary prevention measures and
educational classes as previously described [19,23].
Patients were followed at 1, 3 and 9 months after ACS.
At each time point, cardiovascular risk factors, treatment,
levels of hsCRP and fibrinogen were recorded, and psychi-
atric interviews were performed. The cardiologists and the
care team were blinded to the depression status over the
9 month follow-up period. Patients with depressive symp-
toms were not treated with antidepressant medication,
due to the lack of evidence of a clear benefit of depression
screening, and of antidepressant medication in this patient
population, on cardiovascular disease (CVD) outcome. In-
stead these patients were sent to a mental health profes-
sional for psychotherapy alone.
End point
To assess the incidence of MDD, the psychologist admin-
istered the MINI at 3 days and 1, 3 and 9 months, after an
ACS. The psychologist also conducted the HDRS-17 and
MADRS interviews at 3 days, 1, 3 and 9 months, to score
the intensity and evolution of depression symptoms.
To assess the inflammatory status, hsCRP and fibrino-
gen levels were measured at 3 and 7 days, 1, 3 and
9 months. hsCRP was measured by immuno-turbidimetry,
with a detection limit of 0.02 mg/L (Rock Diagnoses). The
assays were performed blinded to patients’ depression
status; plasma samples drawn at baseline were frozen
at −70°C for subsequent measurement of inflammatory
[19] markers.
The 9-month survival status was determined for all
patients after their ACS. Cause of death was established
from hospital and general practitioner records and death
certificates. Deaths were classified as cardiac or non-
cardiac by a consulting cardiologist blinded to baseline
data.
Statistics
Continuous variables were described by mean and stand-
ard deviation, and compared using Student’s t tests.
Categorical variables were described by numbers and pro-
portions, and compared using Chi-square tests. Compari-
sons were considered statistically significant when the p
value was <0.05, and corrected according to the Bonfer-
roni rule in case of multiple testing. The incidence rate
of MDD was estimated by the proportion of patientspresenting with at least one positive MINI at any time
point divided by the total number of patients followed
during the 9-month period after an ACS. Ninety-five
percent confidence intervals (95% CI) of proportions and
incidence rates were calculated by the exact binomial
method. The association between patient characteristics
and the diagnosis of MDD was assessed by logistic regres-
sion models, using standard recommended methods. The
strength of the association between predictors and MDM
was estimated by calculating the odds ratios (OR) and
their 95% CIs. Linearity of the logit was systematically
checked for every continuous variable. A limited number
of possible predictive variables were chosen on the basis
of previous reports (age, female gender, familial and
personal history of depression, low socio-economic level,
living alone, atherosclerosis burden, LDL cholesterol, meta-
bolic syndrome, smoking and γGT). Their association with
the occurrence of depression was first tested in univariate
logistic regression analysis. Then, all variables associated
with depression with a p value < 0.20 were introduced into
the multivariable model. The variable of interest, hsCRP
level at discharge, was forced into the model. The full
model was kept without further selection, as the aim was
to obtain an estimate of the association of hsCRP with de-
pression, adjusted based on possible confounding factors.
In cases where there was missing data for either hsCRP
or MINI, sensitivity analyses were carried out. Exploratory
analysis of the association between the evolution of
depressive symptoms, as assessed by MADRS, and the
evolution of hsCRP was carried out using a mixed lin-
ear model.
All analyses were carried out using SAS® software v9.1.3
(SAS Institute Inc., Cary, North Carolina, USA).
Results
Incidence and time course of depressive symptoms
The study population flow chart is shown in Figure 1. At
the time of ACS, none of the 87 patients included in
the study had a MDD, or a history of MDD less than
6 months before their initial hospitalization. New onset
of depression was recorded in 8.0% of the patients at
1 month, 10.3% at 3 months and 10.3% at 9 months. A
patient was categorized as part of the “depression group”
if he or she had a MDD at any time point during follow
up, as assessed by the MINI. The overall 9-month inci-
dence of a MDD was 28.7% [95% CI: 19.5 – 39.4]. At
9 months, 19.5% of patients (prevalence) still met the
criteria for diagnosis of depression.
Patients’ characteristics according to depressive symptoms
status
There were no significant differences in general charac-
teristics and the risk factor profile, between patients who
remained free of MDD (non-depression group) versus
Figure 1 Flow chart of the study population.
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the follow up time points, with the exception of prior
history of depression (Table 1 and Additional file 1:
Table S1). There were significantly more patients in the
depression group who reported having a prior history ofdepression, than in the non-depression group (88%, vs
37.1% p < 0.0001).
There was no association found between depressive
symptom status and atherosclerosis burden (Table 1), or
major cardiovascular events (such as reinfarction, stroke
Table 1 General characteristics, atherosclerosis burden,
acute phase management and medical treatments at
discharge, grouped according to the depression status






Mean Age ± sd (years) 49.0 ± 8.8 52.2 ± 9.2
Female gender (%) 6.4 16.0
Personal history of CV disease (%) 8.1 16.0
Family history of CV disease (%) 17.7 28.0
Personal history of depression (%) 37.1 88.0 **
Familial history of depression (%) 25.8 20.0
Live alone (%) 17.7 24.0
Widow(er)/divorcee/separated (%) 45.1 48.0
Low Socio-economic level (%) 8.0 16.0
Atherosclerosis Burden
Mean number of coronary vessels
>50% stenosis
1.4+/−0.8 1.6+/−0.6
ABI < 0.9 (%) 11 7
Carotid stenosis >20% (%) 18.6 22.2
IMT > 0.7 mm (%) 63 60
ACS treatment
Revascularisation (%) 91.9 92.0
Conventional Treatment (%) 8.1 8.0
Post ACS medications at discharge
Beta-blocker and/or calcium antagonist 96.7% 96.0%
Cholesterol-lowering medication 93.5% 100.0%
Antiplatelet therapy or warfarin 100.0% 100.0%






*p values of tests comparing the “No depression” and “Depression” groups
(Student’s t test for age, Chi square tests for proportions). * p < 0.05;
** p < 0.01.
Table 2 Depression severity and intensity, as measured with
the inflammatory profile, as measured by hsCRP and fibrinog










MADRS 5.5 ± 3 6.9 ± 4 5.7 ± 4 13.9 ±
HDRS-17 6.7 ± 3 9.2 ± 4 9.0 ± 5 14.0 ±
hs-CRP (mg/l) 8.7 ± 8.0 10.1 ± 11.0 2.30 ± 2.3 3.05 ±
Fibrinogen (g/l) 5.22 ± 1.1 5.62 ± 1.2* 3.97 ± 0.7 4.18 ±
*p values of tests comparing the “No depression” and “Depression” groups (Studen
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and 1 stroke occurred in the non-depression group vs.
no event in the depression group).
Acute phase management and optimal medical treat-
ment were similar in both groups of patients (MDD vs.
no depression) at discharge (Table 1) and during the
follow-up period (not shown).
Association between hsCRP and occurrence of major
depressive disorder
According to HDRS-17 and MADRS scales, the majority
of these MDD patients were classified as having mild
to moderate depression (Table 2). No difference in
hsCRP levels was detected between the depression and
non-depression groups at any time-point (Table 2). The
evolution of mean hsCRP levels was similar in the two
groups and even individual values did not show any trend
(Figure 2 and Additional file 1: Figures S1 and S2). In uni-
variate, unadjusted analysis, hsCRP measured at day 7 was
not associated with the occurrence of a MDD during the
9-month follow-up period after the ACS. The odds ratio
for a MDD during the first 3 months was 0.96 (95% CI:
0.88 - 1.05; p = 0.37) and the odds ratio for a MDD during
the first 9 months was 1.02 (95% CI: 0.97 - 1.07; p = 0.53)
(Table 3). We also estimated the association between
hsCRP measured at 1 and 3 months and the occurrence of
a MDD during the first 3 or 9 months, but all odds ratios
were close to 1 and not statistically significant (Table 3).
In multivariable analysis, i.e. when taking into account
other characteristics, hsCRP was not associated with the
occurrence of MDD during the first nine months period
after ACS. The adjusted OR was 1.07 (95% CI: 0.77 -1.48;
p = 0.70) (Table 4).
Statistics were done on 87 of 98 patients originally in-
cluded. Eleven patients were not analysed because at
least one MINI was missing at a time point. Sensitivity
analyses were carried out by replacing missing values on
MINI and hsCRP according to different strategies. All
11 missing depression statuses were replaced by absence,
then by presence of depression, without generating a
significant association between hsCRP D7 and 9-monthHDRS-17 and MADRS scales (mean ± sd) and evolution of










8* 6.2 ± 4 18.2 ± 8** 5.5 ± 5 21.0 ± 8**
7* 8.6 ± 5 17.2 ± 7* 7.5 ± 5 20.1 ± 5**
4.2 2.12 ± 2.5 2.27 ± 3.8 2.65 ± 6.4 2.46 ± 3.4
1.1 3.65 ± 0.6 3.62 ± 1.0 3.69 ± 0.8 4.16 ± 0.8*
t’s t test for age, Chi square tests for proportions). *p < 0.05; **p < 0.01.
Figure 2 Comparison of hsCRP evolution (mean+/− SD) in the
group of patient with no depression versus patients with
depression.
Table 4 Multivariable analysis of association between the
depression status over a 9-month follow-up period after
ACS and variables recorded at day 7
Variables measured at D7 OR [95% CI]
hsCRP at D7 1.07 [0.77 - 1.48]
Gender (women) 1.55 [0.21 – 11.35]
Personal history of depression 11.02 [2.74 - 44.34]*
γGT > = 50 2.30 [0.67 – 7.89]
HDRS-17 1.08 [0.92 - 1.26]
*p < 0.001.
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hsCRP D7 were replaced by the highest hsCRP value
(46.3) for the patients of the depressed group and the
lowest hsCRP value (0.3) for the patients of the non-
depressed group, no significant association was found.
Moreover, we found no association between hsCRP at
day 7 and either HDRS-17 or MADRS scores at months
1, 3 and 9 (not shown). We also used a mixed linear
model for studying the association between the evolution
of depressive symptoms, as assessed by MADRS, and the
evolution of hsCRP, between inclusion and one-month
follow-up. No association was found (p = 0.69). The
evolution of hsCRP values was quite similar after the
one-month follow-up (Figure 2).Table 3 Univariate association between hsCRP or fibrinogen
measured at 3 or 7 days, 1 and 3 months (as indicated) and
the occurrence of a MDD during the first 3 or 9 months
Variable Time of depression OR IC 95% p-value
hsCRP D7 In the first 3 months 0.96 [0.88 ; 1.05] 0.37
hsCRP D7 In the first 9 months 1.02 [0.97 ; 1.07] 0.53
hsCRP M1 In the first 3 months 0.90 [0.67 ; 1.20] 0.46
hsCRP M1 In the first 9 months 1.08 [0.93 ; 1.26] 0.32
hsCRP M3 In the first 3 months 0.85 [0.61 ; 1.20] 0.36
hsCRP M3 In the first 9 months 1.02 [0.86 ; 1.20] 0.84
Variable Time of depression OR IC 95% p-value
Fibrinogen D3 In the first 3 months 1.01 [0.60 ; 1.69] 0.97
Fibrinogen D3 In the first 9 months 1.38 [0.92 ; 2.08] 0.12
Fibrinogen M1 In the first 3 months 0.78 [0.39 ; 1.56] 0.49
Fibrinogen M1 In the first 9 months 1.22 [0.72 ; 2.09] 0.46
Fibrinogen M3 In the first 3 months 0.70 [0.33 ; 1.51] 0.37
Fibrinogen M3 In the first 9 months 0.89 [0.48 ; 1.66] 0.71Patients diagnosed as depressed at any time point, had
higher fibrinogen levels at baseline and at their 9 months
assessment, than their non-depressed counterparts, but
this difference was not statistically significant at 1 and
3 month assessment (Table 2). Moreover, there was no
significant association between fibrinogen values and the
occurrence of depression during different periods of time,
as analyzed by univariate logistic regression (Table 3).
Predictive factors of a major depressive disorder during
the 9 months following an ACS
We evaluated the association between quantitative and
non-quantitative characteristics and CV risk factors of
the population, as well as parameters of atherosclerosis
burden, with MDD occurrence. A limited number of pos-
sible predictive variables were chosen on the basis of pre-
vious reports in the literature. In univariate (Additional
file 1: Table S2) as well as in the above-mentioned multi-
variable analyses (Table 4), only the personal history of
depression (more than 6 month before ACS) was sig-
nificantly associated with the onset of a depressive epi-
sode during the 9-month follow-up period, with an OR
of 11.02 (95% confidence interval [CI], 2.74 to 44.34; p =
0.0009) adjusted for gender, hsCRP, Gamma-GT at day 7
and HDRS-17 score at inclusion (Table 4).
Discussion
The aim of this study was to determine whether or not
atherosclerosis-induced inflammation plays a role in the
mediation of MDD and, to examine predictive markers
of depression after an ACS. To our knowledge, this is
the first study to assess the prognostic importance of
hsCRP (and fibrinogen) in the development of MDD after
an ACS. This study included only patients without a
current, or recent (within 6-months) past history, of de-
pression, as determined by a structured clinical interview.
All patients were provided with optimal treatment for
their cardiovascular disease.
Although the incidence of depression was high, we found
no association between hsCRP or fibrinogen and MDD
after an ACS. Therefore, the present data do not support
the hypothesis that hsCRP or fibrinogen (as surrogates of
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after ACS in a population treated with optimal medication
nor that the reported prognostic impact of depression can
be explained by these markers. The only factor associated
with depression occurrence after an ACS was a previous
personal history of depression.
Time course and incidence of depression
A comprehensive literature review of hospitalized post-MI
patients, revealed a prevalence rate for MDD of approxi-
mately 20%, when measured using clinical interviews
[24,25]. Our results show that, in the 9 months following
an ACS, 28.7% of patients developed MDD. We chose to
exclude patients with a history of depression within the
last six months and those who were depressed at the time
of initial hospitalization for their ACS [26]. Therefore, this
study highlights the high incidence of new cases of MDD
after an ACS and the long delay in occurrence after the
onset of ACS.
Inflammation as assessed by levels of hsCRP and
fibrinogen is not likely to be the mechanism underlying
depression
Depression can be a risk factor for the development of
CAD, and often exacerbates the outcome, when present
in patients with established CAD [7-9]. Atherosclerosis is
fundamentally an inflammatory disease and inflammatory
markers are powerful predictors of CAD events [10,11].
Depression and inflammation have each been independ-
ently associated with CAD [6,12,13,15,17,18,27-33]. The
interplay between depression, inflammation, and CVD or
mortality is complex, and may be analyzed in several dif-
ferent ways based on literature [6-13,15,17,18,27-32] : (i)
depression may induce inflammation, and the latter
mediate independently the relationship between de-
pression and CVD; (ii) both depression and inflamma-
tion may cause CVD but through separate pathways,
being synergistic or not; (iii) depression and inflamma-
tion may have a common precursor that is linked to
CVD; or (iv) inflammation may cause depression and
each may or may not have a causal role on CVD [6].
The primary focus of this study was to determine whether
or not inflammation may cause depression, because of the
importance of inflammation in atherosclerosis. In this study,
we found no significant association between atherosclerosis
burden, hsCRP or fibrinogen levels at any time point and
depressive symptoms after an ACS. The point estima-
tion of the OR was close to one (1.07), favoring the
conclusion of an absence of association. However, due
to the limited number of patients, the precision of the
estimate was low (95% confidence interval: 0.77 - 1.48).
Various sensitivity analyses were conducted by imputing
extreme values for missing data but none resulted in an as-
sociation between hsCRP and MDD. Exploratory analysesdid not show an association between the evolution of
hsCRP and the evolution of depression scales. These ar-
guments reinforce the confidence in this null result.
Therefore, this study supports the hypothesis that pa-
tients after an ACS may have a MDD independent of
an elevated hsCRP or fibrinogen level.
These data are in contrast to epidemiological and clin-
ical studies which have suggested that inflammation pre-
cedes the occurrence of depression as in patients with
cancer treated with immunotherapy [17,18,27,29,33,34].
Previous studies on atherosclerosis, inflammation and
depression [6] have been limited to selected clinical sam-
ples and/or have failed to control for important confound-
ing factors [12]. It is not clear to what extent these
associations are due to coexisting cardiovascular risk
factors and comorbidity, or the greater severity of ath-
erosclerotic disease among patients with depression [6].
There are several factors which may explain why our
results are not consistent with these previous reports of
the association between ACS, depression, and biomarkers
of inflammation.
In our study, we used a structured diagnostic interview,
the gold standard for defining clinical depression, while
very few reports in the literature have used an interview-
based study to examine the relationships between CVD,
depression and inflammation. The majority of studies have
used self-reported questionnaires such as the Beck
Depression Inventory, to define depression, which are
not specific for clinical depression. Thus, an elevated
score may reflect transient sadness, anxiety, other psychiatric
disorders, general distress secondary to a life-threatening ex-
perience, or even the symptoms of the medical illness [35].
In our study, patients who had a diagnosis of depression
at study entry were excluded. If individuals with a known
diagnosis of depression were not excluded, the cohorts
would have had a greater prevalence of depression, than
those where only individuals without clinically recognized
depression were screened, and the relationship with in-
flammation could be skewed [26].
We also assessed depression at four time points, where
as in the majority of studies examining the interaction of
depressive symptoms with inflammation in patients with
ACS have measured depressive symptoms only at the
time of the hospitalization for ACS. Depressive symptoms
at this stage may reflect transient “reactive” depression
that may undergo spontaneous remission [5].
Finally, the association between depression and inflam-
mation reported in the literature could be explained by
inconsistencies in monitoring risk factors for CVD, co-
morbidity, and CAD severity [6]. In our study we were
able to control these factors, which could confound the
association between depression and inflammation [6].
One difficulty in interpretation of reports in the litera-
ture, is the impact of medication such as statins [36]. In
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also act as immunomodulators with pronounced anti-
inflammatory properties [37]. Because of the optimal
medical treatment provided to all patients during the
9 month follow-up period, we were able to minimize these
confounding factors.
Identifying a marker of depression onset after ACS to
improve screening
Due to the negative impact of depression on CVD out-
come, in patients with CAD, identifying the onset of a
MDD is particularly relevant for prevention and inter-
vention [25,26,38-40].
Among all the markers tested in our model only per-
sonal history of depression was strongly associated with
the occurrence of a MDD during the 9 months following
an ACS. Personal history of depression identified patients
with a greater vulnerability that were prone to depression.
This marker is easy to assess, and may allow physicians to
determine which patients could benefit from depression
screening.
Limitation of the study
We acknowledge that this study has a limited number of
patients that limit the power of some of statistical analyses
and conclusions, namely in showing associations between
clinical parameters and MDD occurrence (i.e. interaction
between CRP and depression depending on the gender).
It is worth noting that levels of hsCRP and fibrinogen
may not recapitulate all inflammatory processes, namely
central nervous system inflammation. On the other hand,
most often an increase in the levels of TNF-α, IL-1β or
IL-6 will result in an increase in hsCRP or fibrinogen
levels. However, it may be interesting to introduce other
inflammatory markers in future studies.
This study is an exploratory study that may generate
new knowledge and hypothesis, but it needs to be
replicated.
Conclusions
The present study demonstrates that after an ACS, pa-
tients treated with optimal medication can have a MDD
independent of elevated levels of hsCRP or fibrinogen.
Our data does not support the hypothesis that inflamma-
tion is a trigger for depression after ACS. Personal history
of depression may be a good marker to select patients
who should be screened for depression after an ACS.
Additional file
Additional file 1: Table S1. Cardiovascular risk factor profile of the
population. Patients were classified according to their depressive disorder
status. A patient was considered as “depression” if they had a major
depression disorder at any time point during the follow up. (* p<.05,comparison between depression and non depression group for each
time point). Table S2: Univariate analysis of the association between the
depression status over a 9-month follow-up after ACS and variables recorded
at day 7. Figure S1: hsCRP evolution in patients with no depression, during
the 9-month follow-up period. Figure S2: hsCRP evolution in patients with at
least one MINI positive, during the 9-month follow-up period.
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